Every article, report, and earnings note where ACRS appears.
2 articles
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ACRS Report